Comparative Pharmacology
Head-to-head clinical analysis: ETOMIDATE versus KETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETOMIDATE versus KETAMINE HYDROCHLORIDE.
ETOMIDATE vs KETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
None Documented
None Documented
Clinical Note
moderateEtomidate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate."
Clinical Note
moderateEtomidate + Clemastine
"The risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine."
Clinical Note
moderateEtomidate + Venlafaxine
"Etomidate may decrease the antihypertensive activities of Venlafaxine."
Clinical Note
moderateEtomidate + Nefazodone
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone."